Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results

Johnson & Johnson reports lower mortality rates with Impella heart pumps (JNJ:NYSE)

Johnson & Johnson says new Impella analyses show lower mortality in high-risk PCI.

Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results

Analyses presented at TCT highlight how patient selection, timely Impella support and consistent care protocols may

J&J data show lower mortality with Impella in HRPCI than CHIP-BCIS3

J&J presented three clinical analyses at TCT 2026 showing lower mortality with Impella heart pump support in HRPCI patients.

Impella Analyses Show Lower Mortality in High-Risk Heart Procedures

The analyses compared mortality among patients receiving the heart-pump support with rates reported in the recent CHIP-BCIS3 trial.